Jim Cramer reveals how the Fed's rose-colored glasses could impact your money. » Read More
By: Thomas Franck
Popular marijuana stocks fell across the board Wednesday even as Canada became the largest country to legalize the recreational use of cannabis. » Read More
Pfizer's offering early retirement ahead of layoffs early next year, it announced internally to employees Tuesday. The company, which currently employs more than 90,000 workers, didn't say how many people it plans to cut. » Read More
CNBC's Meg Tirrell looks into Valeant Pharma's appointment of Joseph Papa to CEO, as well as Sarepta's showdown with the FDA over a muscular dystrophy drug.
Perrigo plummeted 13 percent in the premarket Monday after issuing very weak guidance.
Sarepta Therapeutics's Eteplirsen is in front of the FDA advisory committee today for a vote on whether the drug is effective in treating Duchenne muscular dystrophy, reports CNBC's Meg Tirrell.
Theranos offers a reminder of the perils of investing in Silicon Valley, where it's common for founders to control a company, the NYT reports.
Sarepta was down sharply a day after an FDA advisory committee voted against recommending the company's Duchenne muscular dystrophy drug.
CNBC's Meg Tirrell reports on the possibility of Perrigo CEO Joseph Papa heading over to Valeant, as well as biotech firm Interxon feeling some pressure after the release of a report calling it 'the new Theranos.'
Raghuram Selvaraju, H.C. Wainwright senior biotechnology analyst, talks about Valeant offering the CEO position to Perrigo's Joseph Papa.
Jim Stewart, CNBC Contributor and The New York Times Columnist, talks about the struggling relationship between Walgreens and Theranos.
Drugmaker Valeant Pharmaceuticals is seeking to appoint Perrigo boss Joseph Papa as its new chief executive, a source familiar with the matter said.
Pharma company Valeant has been under fire recently, but this investor says it's a buy.
Shares of Sarepta Therapeutics plunge after the FDA maintains its "negative" outlook on the company's drug for a rare muscle-wasting disorder.
Actelion CEO Jean-Paul Clozel discusses its latest drug developments and why 2016’s first quarter was “key” for the company.
Actelion CEO, Jean-Paul Clozel talks about the changing face of the M&A space for pharmaceuticals and biotech and clearing the air on what really happened with ZS Pharma.
Dick Kovacevich defended the embattled lab testing start-up's boss, Elizabeth Holmes, saying her treatment recently has been unfair.
The broader U.S. stock market has only seen slight gains this year, but shares of GW Pharmaceuticals are flying high in 2016.
When it comes to the explosion of opioid abuse in the U.S., large employers are footing a big chunk of the bill.
Federal prosecutors are looking into whether the blood-testing start-up misled investors.
Federal regulators are investigating blood-testing start-up Theranos over whether it misled investors.
Bill Miller said the troubled pharmaceutical company should be worth about double its current trading price.
Bill Miller, LMM LLC Chairman & CIO, talks about his view that stock in the beleaguered company Valeant Pharmaceuticals is worth at least $60.